JPS59130215A - 錐体外運動障害の軽減法 - Google Patents
錐体外運動障害の軽減法Info
- Publication number
- JPS59130215A JPS59130215A JP58242302A JP24230283A JPS59130215A JP S59130215 A JPS59130215 A JP S59130215A JP 58242302 A JP58242302 A JP 58242302A JP 24230283 A JP24230283 A JP 24230283A JP S59130215 A JPS59130215 A JP S59130215A
- Authority
- JP
- Japan
- Prior art keywords
- buspirone
- extrapyramidal
- movement disorder
- extrapyramidal movement
- catalepsy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 claims description 25
- 208000016285 Movement disease Diseases 0.000 claims description 17
- 229960002495 buspirone Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 10
- 208000027776 Extrapyramidal disease Diseases 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229960001768 buspirone hydrochloride Drugs 0.000 claims description 8
- 210000000653 nervous system Anatomy 0.000 claims description 7
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 231100000252 nontoxic Toxicity 0.000 claims 2
- 230000003000 nontoxic effect Effects 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000009132 Catalepsy Diseases 0.000 description 20
- 206010047853 Waxy flexibility Diseases 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 16
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 8
- 238000011282 treatment Methods 0.000 description 7
- 241000700159 Rattus Species 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002249 anxiolytic agent Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229960003638 dopamine Drugs 0.000 description 4
- 208000022084 motor paralysis Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 3
- 230000000949 anxiolytic effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229950000688 phenothiazine Drugs 0.000 description 3
- -1 pyrimidine compound Chemical class 0.000 description 3
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001713 cholinergic effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- ZEWQUBUPAILYHI-UHFFFAOYSA-N trifluoperazine Chemical compound C1CN(C)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 ZEWQUBUPAILYHI-UHFFFAOYSA-N 0.000 description 2
- 229960002324 trifluoperazine Drugs 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000031872 Body Remains Diseases 0.000 description 1
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 1
- 241001397104 Dima Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000006083 Hypokinesia Diseases 0.000 description 1
- 208000015592 Involuntary movements Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010047697 Volvulus Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229910001573 adamantine Inorganic materials 0.000 description 1
- 230000003270 anti-cataleptic effect Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000018300 basal ganglia disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 1
- 229960002802 bromocriptine Drugs 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002903 catalepsic effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- WTVNFKVGGUWHQC-UHFFFAOYSA-N decane-2,4-dione Chemical compound CCCCCCC(=O)CC(C)=O WTVNFKVGGUWHQC-UHFFFAOYSA-N 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000000534 dopa decarboxylase inhibitor Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 210000004744 fore-foot Anatomy 0.000 description 1
- 230000003483 hypokinetic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 201000007647 intestinal volvulus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 1
- 229940000041 nervous system drug Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 238000012346 open field test Methods 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000000506 psychotropic effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 230000021542 voluntary musculoskeletal movement Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/452,686 US4438119A (en) | 1982-12-23 | 1982-12-23 | Method for alleviation of extrapyramidal motor disorders |
| US452686 | 1982-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59130215A true JPS59130215A (ja) | 1984-07-26 |
| JPH0422889B2 JPH0422889B2 (enExample) | 1992-04-20 |
Family
ID=23797489
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58242302A Granted JPS59130215A (ja) | 1982-12-23 | 1983-12-23 | 錐体外運動障害の軽減法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4438119A (enExample) |
| JP (1) | JPS59130215A (enExample) |
| AU (1) | AU556112B2 (enExample) |
| BE (1) | BE898540A (enExample) |
| DE (1) | DE3346237A1 (enExample) |
| PH (1) | PH18968A (enExample) |
| ZA (1) | ZA839451B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4634703A (en) * | 1985-10-25 | 1987-01-06 | Bristol-Myers Company | Method for alleviation of panic disorders |
| US4640921A (en) * | 1986-02-04 | 1987-02-03 | Bristol-Myers | Treatment of sexual dysfunction with buspirone |
| US4687772A (en) * | 1986-10-07 | 1987-08-18 | Bristol-Myers Company | Method for improvement of short term memory |
| US4777173A (en) * | 1987-03-25 | 1988-10-11 | Bristol-Myers Company | Method for treatment of alcohol abuse |
| DE3736974A1 (de) * | 1987-10-31 | 1989-05-11 | Troponwerke Gmbh & Co Kg | Verwendung von 2-pyrimidinyl-1-piperazin-derivaten |
| US5468749A (en) * | 1988-08-30 | 1995-11-21 | Gawin; Frank H. | Method for treatment of substance addiction |
| US6432956B1 (en) | 1990-02-12 | 2002-08-13 | William C. Dement | Method for treatment of sleep apneas |
| US5633009A (en) * | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
| US5824680A (en) * | 1991-08-31 | 1998-10-20 | Bayer Aktiengesellschaft | Ipsapirone for the treatment of alzheimer's disease by improving memory |
| US5631017A (en) * | 1993-03-26 | 1997-05-20 | Beth Israel Deaconess Medical Center, Inc. | Topical application of buspirone for treatment of pathological conditions associated with immune responses |
| US5484788A (en) * | 1993-03-26 | 1996-01-16 | Beth Israel Hospital Association | Buspirone as a systemic immunosuppressant |
| US5637314A (en) * | 1995-06-07 | 1997-06-10 | Beth Israel Deaconess Medical Center, Inc. | Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis |
| UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
| US7053092B2 (en) | 2001-01-29 | 2006-05-30 | Otsuka Pharmaceutical Co., Ltd. | 5-HT1a receptor subtype agonist |
| ATE352302T1 (de) * | 2001-07-26 | 2007-02-15 | Merck Patent Gmbh | Verwendung von 2- 5-(4-fluorphenyl)-3- pyridylmethylaminomethyl-chroman und seiner physiologisch annehmbaren salze |
| AR033485A1 (es) | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| PE20070523A1 (es) * | 2005-09-12 | 2007-06-28 | Wyeth Corp | Formulacion de liberacion sostenida del glucuronato de (8-{4-[3-(5-fluoro-1h-indol-3-il)-propil]-piperazin-1-il}-2-metil-4h-benzo[1,4]oxazin-3-ona |
| GT200600416A (es) * | 2005-09-12 | 2007-09-20 | Sales salicilato y gentisato de un compuesto de piperazina | |
| GT200600414A (es) * | 2005-09-12 | 2007-09-20 | Sal de glucuranato de compuesto de piperazine | |
| CN103402514B (zh) * | 2010-10-15 | 2016-01-13 | 康特拉医药公司 | 用于治疗运动障碍的血清素受体激动剂组合物 |
| MY169068A (en) | 2012-04-18 | 2019-02-12 | Contera Pharma Aps | Orally available pharmaceutical formulation suitable for improved management of movement disorders |
| HUE039750T2 (hu) * | 2014-06-26 | 2019-02-28 | Contera Pharma Aps | Hidroxi-buspiron mozgászavarok kezelésére |
| CN109689036B (zh) | 2016-07-11 | 2026-06-19 | 康特拉医药股份有限公司 | 用于治疗早晨运动不能的脉冲药物输送系统 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54163587A (en) * | 1978-05-22 | 1979-12-26 | Bristol Myers Co | Buspirone antiineurosis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
| US3976776A (en) | 1972-12-06 | 1976-08-24 | Mead Johnson & Company | Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones |
-
1982
- 1982-12-23 US US06/452,686 patent/US4438119A/en not_active Expired - Lifetime
-
1983
- 1983-12-20 ZA ZA839451A patent/ZA839451B/xx unknown
- 1983-12-21 DE DE19833346237 patent/DE3346237A1/de not_active Withdrawn
- 1983-12-22 BE BE0/212106A patent/BE898540A/fr not_active IP Right Cessation
- 1983-12-22 AU AU22793/83A patent/AU556112B2/en not_active Expired
- 1983-12-23 JP JP58242302A patent/JPS59130215A/ja active Granted
- 1983-12-23 PH PH30027A patent/PH18968A/en unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54163587A (en) * | 1978-05-22 | 1979-12-26 | Bristol Myers Co | Buspirone antiineurosis |
Also Published As
| Publication number | Publication date |
|---|---|
| BE898540A (fr) | 1984-06-22 |
| AU2279383A (en) | 1984-06-28 |
| PH18968A (en) | 1985-11-26 |
| AU556112B2 (en) | 1986-10-23 |
| ZA839451B (en) | 1984-09-26 |
| DE3346237A1 (de) | 1984-07-05 |
| US4438119A (en) | 1984-03-20 |
| JPH0422889B2 (enExample) | 1992-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0422889B2 (enExample) | ||
| Redmond et al. | Fetal neuronal grafts in monkeys given methylphenyltetrahydropyridine | |
| AU2017210644B2 (en) | Autoimmune disorder treatment using RXR agonists | |
| US5116852A (en) | Treatment of sleep disorders | |
| Bonta et al. | 1-Hydroxy-3-amino-pyrrolidone-2 (HA-966): a new GABA-like compound, with potential use in extrapyramidal diseases | |
| JPH05201859A (ja) | 神経障害治療剤 | |
| DE69808619T2 (de) | Prostaglandin-pharmazeutische-zusammensetzungen | |
| JP2004518653A (ja) | 不安障害を治療する方法 | |
| AU3715000A (en) | Method for treating exercise induced asthma | |
| US20250352540A1 (en) | Uses of a pure 5-ht6 receptor antagonist | |
| Tainter | Effects of certain analeptic drugs on spontaneous running activity of the white rat. | |
| JPH09323927A (ja) | 慢性閉塞性動脈硬化症の治療のためのカルニチン誘導体含有薬剤 | |
| JP2002518442A (ja) | 偏頭痛及び情動病の治療及び予防用バルプロ酸類似物の用法 | |
| US6143782A (en) | Anti-inflammatory and anti-asthma treatment with reduced side effects | |
| Hill et al. | Reduction of pain-conditioned anxiety by analgesic doses of morphine in rats | |
| US6670394B1 (en) | Method for treating COPD | |
| UA42686C2 (uk) | Похідні 3-хінуклідилових ефірів, проміжні сполуки та спосіб одержання 3-хінуклідилових ефірів, фармацевтична композиція, що має антимускаринову дію, та спосіб лікування хронічних обструктивних захворювань дихальних шляхів або астми | |
| Mendelson et al. | Lifetime monoamine oxidase inhibition and sleep | |
| JPH02504146A (ja) | 勃起不全用フラボキセイトおよび誘導体 | |
| CN109310669B (zh) | 氨基甲酸酯化合物用于预防或治疗三叉神经痛的用途 | |
| JPH05506441A (ja) | 加齢関連記憶障害およびその他の認識障害の治療のための化合物 | |
| WO1997002822A1 (en) | Drug for ameliorating brain diseases | |
| EP0442424B1 (en) | Treatment of sleep apneas with azapirone derivatives | |
| WO2024006841A2 (en) | Compositions for weight loss and cancer treatment | |
| DE4436127A1 (de) | Verwendung von aromatischen Amiden und Säuren zur Behandlung von rheumatischen Erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EXPY | Cancellation because of completion of term |